UK markets open in 2 hours 17 minutes

IceCure Medical Ltd (ICCM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.7600+0.0020 (+0.26%)
At close: 04:00PM EDT
0.7410 -0.02 (-2.50%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.7580
Open0.7848
Bid0.7486 x 100
Ask0.7705 x 100
Day's range0.7580 - 0.7848
52-week range0.5200 - 1.5700
Volume155,279
Avg. volume421,995
Market cap36.434M
Beta (5Y monthly)3.00
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

    IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the U.S. Food and Drug Administration ("FDA") will convene a Medical Device Advisory Committee for a panel meeting (the "Advisory Panel") to obtain independent expert advice on scientific, technical, and policy matters related to ProSense® t

  • PR Newswire

    IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

    IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the three months ended March 31, 2024. During the quarter, the Company completed its landmark ICE3 trial and recently achieved several objectives, including: publishing and submitting the full data set of its I

  • PR Newswire

    IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

    IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024. The Company will discuss such results and other corporate dev